Cargando…

Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma

Background and Objectives: Intrahepatic cholangiocarcinoma (iCCA) is a pernicious tumor characterized by a dismal outcome and scarce therapeutic options. To substantially improve the prognosis of iCCA patients, a better understanding of the molecular mechanisms responsible for development and progre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cigliano, Antonio, Pilo, Maria Giulia, Mela, Marta, Ribback, Silvia, Dombrowski, Frank, Pes, Giovanni Mario, Cossu, Antonio, Evert, Matthias, Calvisi, Diego Francesco, Utpatel, Kirsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023300/ https://www.ncbi.nlm.nih.gov/pubmed/31861475 http://dx.doi.org/10.3390/medicina56010001

Ejemplares similares

The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease
por: Cigliano, Antonio, et al.
Publicado: (2022)

Correction: The Hippo pathway efector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease
por: Cigliano, Antonio, et al.
Publicado: (2023)

Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model
por: Dong, Mingjie, et al.
Publicado: (2018)

CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype
por: Mancarella, Serena, et al.
Publicado: (2022)

The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models
por: Ribback, Silvia, et al.
Publicado: (2016)

Correction: CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype
por: Mancarella, Serena, et al.
Publicado: (2023)

Early Subcellular Hepatocellular Alterations in Mice Post Hydrodynamic Transfection: An Explorative Study
por: Yasser, Mohd, et al.
Publicado: (2023)

Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis
por: Mancarella, Serena, et al.
Publicado: (2020)

Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice
por: Hu, Junjie, et al.
Publicado: (2016)

SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice
por: Delogu, Salvatore, et al.
Publicado: (2014)

Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice
por: Cigliano, Antonio, et al.
Publicado: (2017)

PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men
por: Ribback, Silvia, et al.
Publicado: (2015)

Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans
por: Che, L, et al.
Publicado: (2016)

Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver
por: Li, Xiaolei, et al.
Publicado: (2015)

Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway
por: Xu, Zhong, et al.
Publicado: (2018)

MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment
por: Wang, Pan, et al.
Publicado: (2019)

Fascin1 empowers YAP mechanotransduction and promotes cholangiocarcinoma development
por: Pocaterra, Arianna, et al.
Publicado: (2021)

Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis
por: Cigliano, Antonio, et al.
Publicado: (2017)

Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: Implications for the treatment of human liver cancer
por: Wang, Chunmei, et al.
Publicado: (2013)

Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans
por: Che, Li, et al.
Publicado: (2020)

Hepatocellular glycogenotic foci after combined intraportal pancreatic islet transplantation and knockout of the carbohydrate responsive element binding protein in diabetic mice
por: Ribback, Silvia, et al.
Publicado: (2017)

Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development
por: Liu, Pin, et al.
Publicado: (2017)

Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System
por: Lamarca, Angela, et al.
Publicado: (2021)

Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis
por: Jia, Jiaoyuan, et al.
Publicado: (2020)

Transcriptomic and Proteomic Analysis of Clear Cell Foci (CCF) in the Human Non-Cirrhotic Liver Identifies Several Differentially Expressed Genes and Proteins with Functions in Cancer Cell Biology and Glycogen Metabolism
por: Metzendorf, Christoph, et al.
Publicado: (2020)

Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy
por: Scheiter, Alexander, et al.
Publicado: (2021)

Wnt/β-Catenin-Pathway Alterations and Homologous Recombination Deficiency in Cholangiocarcinoma Cell Lines and Clinical Samples: Towards Specific Vulnerabilities
por: Scheiter, Alexander, et al.
Publicado: (2022)

Pathogenetic and Prognostic Significance of Inactivation of RASSF Proteins in Human Hepatocellular Carcinoma
por: Calvisi, Diego F., et al.
Publicado: (2012)

Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma
por: Che, Li, et al.
Publicado: (2019)

Corrigendum: Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma
por: Che, Li, et al.
Publicado: (2022)

Functional role of SGK3 in PI3K/Pten driven liver tumor development
por: Cao, Hui, et al.
Publicado: (2019)

RASSF1A independence and early galectin‐1 upregulation in PIK3CA‐induced hepatocarcinogenesis: new therapeutic venues
por: Scheiter, Alexander, et al.
Publicado: (2021)

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
por: Shang, Runze, et al.
Publicado: (2021)

The c-MYC Protooncogene Expression in Cholesteatoma
por: Palkó, Enikő, et al.
Publicado: (2014)

eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma
por: Steinmann, Sara M., et al.
Publicado: (2023)

Identification of DUSP4/6 overexpression as a potential rheostat to NRAS-induced hepatocarcinogenesis
por: Klemm, Sophie, et al.
Publicado: (2023)

Serum Markers of Intrahepatic Cholangiocarcinoma
por: Malaguarnera, Giulia, et al.
Publicado: (2013)

Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade
por: Jia, Jiaoyuan, et al.
Publicado: (2017)

Intrahepatic Sarcomatoid Cholangiocarcinoma
por: Malhotra, Shalini, et al.
Publicado: (2010)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rnq6rb6bg870104svnt0559643